Enzychem Lifesciences, Corp
440 Sylvan Ave, STE 290B
Englewood Cliffs
New Jersey
07632
United States
42 articles about Enzychem Lifesciences, Corp
-
Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting
7/25/2022
Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.
-
Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting
4/12/2022
Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.
-
Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting
4/6/2022
Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis
3/9/2022
Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the company has completed the final Clinical Study Report (CSR) for their Phase 2 study of EC-18 in Chemoradiation-induced Oral Mucositis (CRIOM)/.
-
Enzychem Lifesciences Announces Formation of Corporate Advisory Committee
3/2/2022
Enzychem Lifesciences, a clinical-stage biotechnology company, announced the formation of its Corporate Advisory Committee.
-
PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm
1/4/2022
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea.
-
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
11/26/2021
Enzychem Lifesciences and Cadila Healthcare Ltd, a part of the Zydus Group, announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis
10/20/2021
Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).
-
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis
9/13/2021
Enzychem Lifesciences (KOSDAQ: 183490), announced today database lock for the Phase 2 clinical trial of its lead program EC-18 in chemoradiation-induced oral mucositis (CRIOM) had been completed last August.
-
Enzychem Lifesciences Announces Poster Presentation at the 2021 Keystone Symposia Conference
5/20/2021
Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, today announced that it will present a poster at the 2021 Keystone Symposia, " DAMPs Across the Tree of Life Inducing Innate Immunity
-
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program
4/20/2021
Enzychem Lifesciences (KOSDAQ: 183490), a biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, today announced that it has been selected to collaborate with the Chemical Countermeasures Research Program (CCRP) at the National Institute of Allergy and Infectious Diseases (NIAID),
-
Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The International Liver Congress 2021 (EASL)
4/16/2021
Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, announced that it has been selected at the 1 st round of abstract submission to present at The International Liver Congress™ 2021
-
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis
4/6/2021
Enzychem Lifesciences (KOSDAQ: 183490), announced today that it has completed patient enrollment in Stage 2 of its Phase 2 clinical trial of EC-18 in chemoradiation induced oral mucositis (CRIOM).
-
Enzychem Lifesciences Selected to Participate at the 15th New York Health Forum: Investing in Space - Next Frontier of Healthcare
3/11/2021
Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, today announced that an Enzychem Lifesciences representative will be participating as a panelist at the 15 th New York Health Forum
-
Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)
3/1/2021
Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biopharmaceutical company developing innovative medicines to improve the lives of patients with cancer and inflammatory diseases, announced an oral presentation at the 2021 NASH-TAG Conference held virtually on March 11-13, 2021 .
-
Enzychem Lifesciences Announces Poster Presentation At AACR Virtual Annual Meeting 2021
2/8/2021
Enzychem Lifesciences (KOSDAQ: 183490), today announced it will present new study data regarding its lead drug candidate, EC-18 in combination with immune checkpoint inhibitor (ICI) therapy, at the American Association for Cancer Research (AACR) 2021 Annual Meeting, held virtually, April 10-15 and May 17-21.
-
Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space
1/26/2021
Enzychem Lifesciences (KOSDAQ: 183490), announced today that NASA's Human Research Program has awarded $150K in grant funding to conduct research on its lead compound EC-18, and how it impacts astronaut health and performance during future long-duration missions beyond low-Earth orbit.
-
Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021
1/8/2021
Enzychem Lifesciences (KOSDAQ: 183490), announced today that Ki Young Sohn, Chief Executive Officer & Chairman, will be presenting a company overview and participating in virtual one-on-one meetings at Biotech Showcase Digital , held January 11-15, 2021 .